Hospital da Luz Lisboa has initiated recruitment for the SKYPS clinical study, destined to children and youths with Systemic Juvenile Idiopathic Arthritis (SJIA), a systemic chronic inflammatory disease. The trial will be conducted under the coordination of Marta Cabral , physician specialized in paediatric rheumatology. Systemic Juvenile Idiopathic Arthritis, also known as Still’s disease, is a rare disease characterized by episodes of prolonged fever, exanthema, and joint inflammation. In some cases, it may also affect other organs and have a significant impact on the quality of life of children and families. Progress made over the last few decades in understanding the physio-pathological mechanisms of the disease has allowed developing biological therapies that have substantially improved the prognostic of patients. Yet not all children react similarly to the treatments presently available and there are still clinical needs to be met. The SKYPS study intends to assess the safety and effectiveness of sarilumab , an experimental biological drug that acts on one of the inflammatory pathways involved in the disease. The trial is destined to children and youths aged 1 to 17 with a systemic juvenile idiopathic arthritis diagnosis. Participation in clinical trials is fundamental for the development of new therapeutic options and contributes for the advancement of scientific knowledge on rare diseases, enabling to offer patients access to high-quality clinical research. More information on this clinical trial is available at Participar em ensaios clínicos | Hospital da Luz Lisboa . The team conducting the trial is available by e-mail: ensaios.clinicos.learninghealth@hospitaldaluz.pt
